Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P336 | DOI: 10.1530/endoabs.90.P336

1Fundación Jiménez Diaz, Endocrinology and Nutrition, Madrid, Spain; 2Hospital Universitario Infanta Elena, Valdemoro, Spain; 3General Hospital Villalba, Collado Villalba, Spain


Objectives: To evaluate the changes in HbA1c, basal glucose, weight, and lipid profile in patients with type 2 diabetes after starting oral semaglutide.

Methods: This study was conducted in Madrid, Fundación Jiménez Díaz, Infanta Elena and General de Villalba hospitals. A total of 75 patients with type 2 diabetes were included. The mean age was 62.0±10.5 years and 60% were men. The mean duration of diabetes was 7.3±6.6 years, and 66.7% had hypertension, 67.6% had dyslipidemia, 14.9% were smokers, 23.0% had sleep apnea, and 26.4% had microvascular disease. Basal treatment included insulin in 12.0%, metformin in 86.7%, SGLT2i in 48%, DPP4i in 41.9%, GLP1-Ra in 1.3%, repaglinide in 8.1%, and Sulphonylurea in 2.7%. A total of 58.3% of patients reached a dose of 7 mg, and 41.7% reached 14 mg. 4 patients discontinued the treatment, 2 due to adverse effects and 2 due to administrative problems. Gastrointestinal adverse effects were reported in 16% of patients. The study had a follow-up period of 7.3±6.6 months. Paired T-Student test for parametric data (α), Wilcoxon test for non-parametric data (β), and McNemar test for proportions (ф) were used for statistical analysis.

Results: The following changes were observed after starting oral semaglutide:

Comparison
Basal6 monthsDifferences
Basal glucose (mg/dl) α165,0±5,9135,0±5,0-30,0 (95%IC: -41,1 a -19,0) **
HbA1c (%) α7,85± 0,166,67±0,14-1.18 (95%IC: -1,50 a -0.85)**
Weight (kg) α95.1±1,589,8±1,4-5,4 (95%IC: -6.4 a – 4,3)**
BMI (kg/m2) α34.5±0,532.6±0,5-1.9 (95%IC: -2.3 a – 1,6)**
Total Cholesterol (mg/dl) α171,7±5,5153,7±4,3-18,0 (95%IC: -27,8 a – 8,2)**
LDL-cholesterol (mg/dl) α90,8±4,279,0±3,8-11,8 (95%IC: -18,5 a – 5,1)**
Triglycerides (mg/dl) β159(P25-75:121-208)131(P25-75:102-172)-24(95%IC: -38 a -4)**
HbA1c <7% ф33,3%67,1%+34,2% (95%IC: 22,6 a 48,6)**
HbA1c reductions by basal HbA1c α
HbA1c > 7%-1,3 (95%IC: -1,7 a -0,8)**
.HbA1c > 8%-1,6 (95%IC: -2,0 a -1,2)**
HbA1c > 9%-1,8 (95%IC: -2,3 a -1,3)**
** P<0.01; * P<0.05

Conclusions: Oral semaglutide was associated with significant improvements in HbA1c, fasting glucose, weight, and lipid profile in patients with type 2 diabetes. The treatment was well tolerated, with a low incidence of adverse effects. The results of this study support the use of oral semaglutide.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.